Source: Pharmaceutical Technology
Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Thank you.You will receive an email shortly. Please check your inbox to download the Report.
Go deeper with GlobalData
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
The gold standard of business intelligence.
Related Company ProfilesEli Lilly and CoTakeda Pharmaceutical Co LtdAbbVie IncBristol-Myers Squibb CoDICE Therapeutics IncView all
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy
Tick here to opt out of curated industry news, reports, and event updates
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Through the deal – which is expected to close in Q3 2024 – Lilly will inherit Morphic’s lead asset, MORF-057. The candidate is under investigation in two Phase II studies for ulcerative colitis and one Phase II study for Crohn’s disease. The small molecule drug inhibits α4β7, an integrin expressed on some white blood cells. IBD is the umbrella term for two chronic conditions: Crohn’s disease and ulcerative colitis, both of which cause inflammation in the digestive tract. GlobalData estimates that the Crohn’s and ulcerative colitis markets will be worth $25.5bn and $14.7bn by 2032, respectively. See Also:How will a Labour government support the UK clinical trials industry?
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
In the announcement accompanying the acquisition, Lilly’s chief scientific officer Daniel Skovronsky said: “Oral therapies could open up new possibilities for earlier intervention in diseases like ulcerative colitis, and also provide the potential for combination therapy to help patients with more severe disease.” This latest deal comes after a flurry of high-profile acquisitions from Lilly last year, including DICE Therapeutics for $2.4bn in June 2023, where it inherited a preclinical oral α4β7 programme. In October 2023, Lilly signed a definitive agreement for the acquisition of radiopharmaceutical company POINT Biopharma for an all-in cash price of $1.4bn. Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Thank you.You will receive an email shortly. Please check your inbox to download the Report.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy
Tick here to opt out of curated industry news, reports, and event updates
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.